A new Cambridge biotech startup has raised nearly $30 million for the development of synthetic microbes that can treat disease.
Synlogic is developing "synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease," said Ankit Mahadevia, Synlogic's chief executive.
In a statement, the company said it has developed a way for bacteria to "sense physiologic conditions, perform a therapeutic action, and deactivate themselves."
While the company did not specify what diseases it will focus on, it did say its technology could be used to deliver drugs targeted at diseases where traditional methods have been ineffective, and that a focus on the gastrointestinal system "could have merit."
Founded last fall, Synlogic raised $29.4 million in equity financing, led by Atlas Venture and New Enterprise Associates.
Mahadevia founded the company as part of the Atlas Venture incubator.
"The time has come to fulfill the promise of synthetic biology for patients," said Ed Mathers, a partner at New Enterprise Associates.
Anda sedang membaca artikel tentang
Biotech raises $30M for disease-treating bacteria
Dengan url
http://bintanggugel.blogspot.com/2014/07/biotech-raises-30m-for-disease-treating.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Biotech raises $30M for disease-treating bacteria
namun jangan lupa untuk meletakkan link
Biotech raises $30M for disease-treating bacteria
sebagai sumbernya
0 komentar:
Posting Komentar